Login to your account

Username *
Password *
Remember Me
Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less.

Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less.

Bibliographie
25 mai 2021

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial – JAMA Internal Medicine  

The post Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. appeared first on Links Medicus.

Lu 606 fois
Évaluer cet élément
(0 Votes)
Plus dans cette catégorie : « Living systematic review: The evidence is insufficient to determine the benefits and harms of vitamin D supplementation as a treatment of COVID‐19. Mild COVID-19 induces lasting antibody protection, study finds. »

About Author

Zouhair Souissi

Dernier de Zouhair Souissi

Retour en haut

Recherche

Search